This page shows the latest Advate news and features for those working in and with pharma, biotech and healthcare.
The web-based myPKFiT supports the pharma firm's Advate treatment. US regulators have approved Shire’s new web-based dosing software for its recombinant Factor VIII haemophilia A treatment Advate. ... A version of the myPKFiT for Advate software has
The European Commission has approved Shire’s haemophilia A therapy Adynovi, a new long-acting version of its long-established Advate product.
The injectable is a new form of Advate - a haemophilia A treatment Shire acquired from Baxalta in a $32bn takeover - and offers twice-weekly prophylactic use as well as on-demand
to wrest market share from established haemophilia A therapies such as Shire/Baxalta's Advate (octocog alfa).
The merger will couple Baxalta's haemophilia franchise - including its big selling Advate product for haemophilia A and long-acting follow-up BAX-855 which is nearing the market- with Shire
Last month it secured FDA approval for long-acting haemophilia A therapy Adynovate (formerly BAX 855), a follow-up to its big-selling Advate brand.
More from news
Approximately 3 fully matching, plus 21 partially matching documents found.
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...